Lung Cancer

Latest News

The final analysis of the phase 2/3 CCTG IND.227/KEYNOTE-483 trial identified a statistically significant survival benefit with pembrolizumab and chemotherapy vs chemotherapy alone in the first-line setting for patients with unresectable advanced or metastatic malignant pleural mesothelioma.
Pembrolizumab/Chemo Appears to Improve Survival in Advanced Mesothelioma

March 13th 2023

The final analysis of the phase 2/3 CCTG IND.227/KEYNOTE-483 trial identifies a statistically significant survival benefit with pembrolizumab and chemotherapy vs chemotherapy alone in the first-line setting for patients with unresectable advanced or metastatic malignant pleural mesothelioma.

FDA Approves Imaging Agent Designed to Target Tumors in Lung Cancer
FDA Approves Imaging Agent Designed to Target Tumors in Lung Cancer

March 4th 2023

Data from a retrospective study suggests that stereotactic body radiotherapy may be a suitable alternative to surgical resection for patients with primary lung neuroendocrine tumors, according to an expert from Moffitt Cancer Center.
SBRT Provides Positive Locoregional Control in Lung Neuroendocrine Tumors

February 9th 2023

OncobiotaLUNG, a novel liquid biopsy that detects lung cancer, now has a breakthrough device designation from the FDA.
FDA Grants Novel Liquid Biopsy Assay Breakthrough Device Designation to Detect Lung Cancer

January 13th 2023

An expanded indication for pafolacianine as an imaging agent for patients with lung cancer has been approved by the FDA based on findings from the phase 3 ELUCIDATE trial.
Expanded Indication for Pafolacianine Imaging Agent in Lung Cancer Approved by FDA

December 20th 2022

Video Series
Video Interviews
Podcasts
Latest CME Events & Activities

Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers

View More

Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes

View More

Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®

View More

Trekking Through the Latest Updates for ROS1-Targeted Therapies

View More

Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care

View More

Mapping Out the Role of Emerging Biomarkers and Testing in NSCLC

View More

Navigating the Latest Data on NTRK-Targeted Therapies

View More

Community Practice Connections™: 17th Annual New York Lung Cancers Symposium

View More

Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow

View More

Show Me Your Care Plan™: Monitoring and Managing Patients With EGFR Exon20 Insertion+ NSCLC

View More

Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care

View More

Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers

View More

Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care

View More

Advancing Precision Care Through Biomarker-Driven Therapy: CEACAM5 as a Therapeutic Target in NSCLC

View More

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

View More

Medical Crossfire: How Should We Leverage Multidisciplinary Lung Cancer Care Teams in Managing Earlier Forms of NSCLC... When the Goal Is Cure?

View More

Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC

View More

Catching Them Early: A Real-World Case Discussion on the Application of Testing Methodologies to Identify Key Markers Across NSCLC

View More

Expert Illustrations & Commentaries™: Exploring the Clinical Rationale for Antagonizing Inflammatory IL-1-beta Signaling in NSCLC

View More

Onco-Nurse Academy™: Exploring an Advent of Targeted Therapies Across Advanced NSCLC Care and Strategies for Managing Adverse Events Associated With Treatment

View More

Patient, Provider, and Caregiver Connection™: Shedding a Light on the Patient Journey with KRAS Mutated Lung Cancer

View More

Clinical Vignettes®: Multidisciplinary Discussions on the Application of Novel EGFR Exon 20 Targeted Regimens for NSCLC Management

View More

Expert Illustrations & Commentaries™: Exploring the Role of Novel Antibody-Drug Conjugates in Advanced NSCLC

View More

Advances In™ NSCLC: Exploring CEACAM5 As A New Therapeutic Target

View More

Community Practice Connections™: Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!

View More

Community Practice Connections™: Analyzing the Evolving Role of Liquid Biopsies Across Cancer Care

View More

Advances In™: The Role of NRG1 Fusions Across Tumor Types

View More

Medical Crossfire®: Leveraging EGFR Mutation Profiles to Personalize Therapeutic Decisions in Resected and Metastatic NSCLC Settings

View More

Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future

View More

Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!

View More

More News